SHIRE PLC: Transaction in Own Shares

Transaction in Own Shares 
May 16, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that, in accordance with the authority granted by shareholders at the Company's
Annual General Meeting on April 30, 2013, it purchased 45,690 of its ordinary
shares of 5 pence each ("Ordinary Shares") on May 15, 2013 through both direct
purchases of Ordinary Shares, and through the purchase of Ordinary Shares
underlying ADRs. The highest and lowest price paid for the directly acquired
Ordinary Shares was 2063.00 pence per share and 2039.00 pence per share
respectively, and for those Ordinary Shares acquired though the purchase of
ADRs was 3105.67 cents per share and 3082.00 cents per share respectively. 
The purchased shares will be held as treasury shares. Following the above
purchase, the Company holds 8,678,195 Ordinary Shares as treasury shares and
has 554,154,198 Ordinary Shares in issue (excluding treasury shares). 
The purchases were made by an independent third party which makes its trading
decisions independently of, and uninfluenced by, the Company.  The independence
of the third party enables the Company to continue to purchase Ordinary Shares
(including Ordinary Shares underlying ADRs) during close periods and other
prohibited periods, should they arise. The third party has been appointed by
the Company to make purchases to December 31, 2013. 
For further information please contact: 
Investor Relations                                                              
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas. 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
-0- May/16/2013 06:00 GMT
Press spacebar to pause and continue. Press esc to stop.